Background To compare the prognosis of SLE patients who achieve clinically quiescent following treatment, with or without serologically active. Methods We categorized SLE patients from Lupus Clinic of ...

Guillermo Ruiz-Irastorza, Diana Paredes-Ruiz, Fernando Arizpe et al. Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough? Lupus Sci Med 2025;12:e001254. doi: ...

Background Systemic lupus erythematosus (SLE) often mimics the symptoms of other diseases, and the interval between symptom onset and diagnosis remains long in these patients. The aim of this study is ...

Background Around 963 A.D., Bishop Eraclius (Liège, Belgium) wrote an affidavit stating, ‘I … was nearly taken to death by the disease called Lupus.’ On the seventh night of praying at Saint Martin’s ...

Costner M, Sontheimer R, Provost T. Lupus erythematosus. In: Sontheimer R, Provost T, eds. Cutaneous manifestations of rheumatic diseases. Philadelphia: Williams ...

Background Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines (eg, Type 1 IFNs, IL-23, and IL-12) involved in lupus pathogenesis. Deucravacitinib is a first-in-class, oral, selective, ...

Background Non-adherence to medical recommendations in childhood-onset systematic lupus erythematosus (cSLE) is estimated to be between 40%–50%. For patients with ...

Objective To investigate changes in peripheral B cells, B-cell subsets and biomarkers in NOBILITY. Methods In the randomized Phase II NOBILITY trial (NCT02550652), patients with lupus nephritis ...

Background The molecular and cellular heterogeneity of human Lupus Nephritis (LN) at the kidney tissue level makes it challenging to identify key disease drivers and therapeutic targets. Single-cell ...

Objective We investigated DORIS (Definition of Remission in SLE) attainment in patients with SLE in the placebo-controlled phase 3 TULIP long-term extension (LTE) trial of anifrolumab. DORIS ...

Describe the clinical presentation of systemic CLS, including symptoms, signs, and complications Discuss the diagnosis of systemic CLS, including diagnostic tests and criteria.

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids. 2 As ...